Delivery
Delivery time may vary depending on store and country. To learn more about Shipping Policy
Price Range
Vertex is a global biotechnology company that aims to discover and develop innovative medicines for serious diseases. They focus on developing therapies for cystic fibrosis, along with medicines for other serious, life-threatening diseases like sickle cell disease and beta thalassemia.
Founded in 1989 by Joshua Boger
Started as a small research company and became a publicly traded company in 1991
Received FDA approval for their first CF drug, Kalydeco, in 2012
Expanded their CF portfolio with drugs such as Orkambi, Symdeko, and Trikafta
Entered into collaborations with other pharmaceutical companies like CRISPR Therapeutics
Has a global presence with headquarters in Boston, Massachusetts and offices in several other countries
AbbVie is a global biopharmaceutical company that focuses on developing therapies for cancer, immunology, neuroscience, and other diseases. They have a strong presence in the CF market with their drug, Creon.
Galapagos is a biotechnology company that focuses on discovering and developing small molecule medicines for various diseases. They have a collaboration with Gilead Sciences to develop a drug for CF.
Genentech is a biotechnology company that focuses on developing therapies for cancer, immunology, and other diseases. They have a presence in the CF market with their drug, Pulmozyme.
Gilead Sciences is a biopharmaceutical company that focuses on developing therapies for HIV/AIDS, liver diseases, and other diseases. They have a collaboration with Galapagos to develop a drug for CF.
Kalydeco is a drug used to treat cystic fibrosis in patients with specific mutations. It targets the defective protein that causes CF and helps improve lung function and other symptoms.
Orkambi is a drug used to treat cystic fibrosis in patients with specific mutations. It is a combination of two drugs that target the defective protein that causes CF and helps improve lung function and other symptoms.
Symdeko is a drug used to treat cystic fibrosis in patients with specific mutations. It is a combination of two drugs that target the defective protein that causes CF and helps improve lung function and other symptoms.
Trikafta is a drug used to treat cystic fibrosis in patients with specific mutations. It is a combination of three drugs that target the defective protein that causes CF and helps improve lung function and other symptoms. It has been shown to be highly effective in clinical trials.
Vertex is a global biotechnology company that aims to discover and develop innovative medicines for serious diseases, focusing on cystic fibrosis and other life-threatening conditions.
Vertex focuses on developing therapies for cystic fibrosis, sickle cell disease, beta thalassemia, and several other serious, life-threatening diseases.
Vertex's main products include Kalydeco, Orkambi, Symdeko, and Trikafta - all used to treat cystic fibrosis in patients with specific mutations.
Trikafta has been shown to be highly effective in clinical trials, improving lung function and other symptoms in patients with cystic fibrosis with specific mutations.
Vertex's competitors in the cystic fibrosis market include AbbVie with Creon, Galapagos with a drug in development in collaboration with Gilead Sciences, Genentech with Pulmozyme, and Gilead Sciences with a drug in development in collaboration with Galapagos.
